20/20 HealthCare Partners
  • Home
  • Strategic Partners
  • Team
  • Companies
  • News
  • Contact

20/20 HealthCare Partners

21 Oct2019

Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board

Written by 2020HCP.com. Posted in News

BEDFORD Mass., October 21, 2019 — Verseau Therapeutics, Inc. (“Verseau”) launched today with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital. In addition, George Golumbeski, Ph.D., a champion of innovation and former Executive Vice President of Celgene, has been appointed Chairman of the Verseau Board of Directors. Verseau is developing novel, first-in-class immunotherapies that target modulation of macrophages, the master orchestrators of the immune system. The proceeds from the financing will support advancement of Verseau’s macrophage checkpoint modulator (MCM) programs to the clinic. Link to Full Article 

Latest News

  • SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies November 7, 2019
  • Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference November 6, 2019
  • SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology – Activating Antigen Carriers (AACs) November 5, 2019
  • SQZ Biotech Announces Clearance of US IND Application for First Clinical Trial October 22, 2019
  • Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board October 21, 2019

20/20 HealthCare Partners | 2000 Commonwealth Ave, Suite 200, Auburndale, MA 02466 | Contact Us

Copyright © 2019
  • Home
  • Strategic Partners
  • Team
  • Companies
  • News
  • Contact